How many MSM in Europe could benefit from PrEP--a 9 billion Euro question?
HIV/STI Unit, Institute of Tropical Medicine, Antwerp, Belgium Division of Infectious Diseases and HIV Medicine, University of Cape Town, South Africa ckenyon@itg.be.
Chris Richard
CR
Kenyon
HIV/STI Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Kara
K
Osbak
D000293:Adolescent; D044966:Anti-Retroviral Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005060:Europe; D015658:HIV Infections / Q000191:economics / Q000517:prevention & control*; D017048:Health Care Costs / Q000706:statistics & numerical data*; D018451:Homosexuality, Male / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D065129:Pre-Exposure Prophylaxis / Q000379:methods*
D044966:Anti-Retroviral Agents